CytoImmune Therapeutics Ushers in New Era with Appointment of Dr. Jose Eduardo Vidal as CEO to Spearhead Focus on Cell Therapy Development
TOA BAJA, Puerto Rico (PRWEB) July 19, 2023 -- CytoImmune Therapeutics is proud to announce the promotion of Jose Eduardo Vidal, Ph.D. to the dual role of Chief Executive Officer and member of the Board of Directors. Dr. Vidal has been with the company since 2021, serving as Chief Operating Officer and playing a key role in the development of the company's clinical-stage cell immunotherapy.
Following the company’s successful development of a genetically modified NK cell product for lung cancer, now in clinical trials, Dr. Vidal is extending our company’s reach by offering cell therapy development and clinical manufacturing services to biotechnology companies.
Dr. Vidal’s distinguished track record spans over two decades in the biotech industry, specializing in cell therapy, chemistry, manufacturing, and control processes. Prior to joining CytoImmune, he held senior leadership positions at Atara Biotherapeutics and Amgen, where he was instrumental in the development of allogeneic T-cell therapies and oversaw worldwide product development networks.
Under Dr. Vidal's leadership, CytoImmune is committed to fostering advancements in cell therapy and facilitating clients in delivering innovative treatments to patients. With decades of experience working with T cells and natural killer (NK) cells, the team at CytoImmune can modify these cells to express chimeric antigen receptors (CARs), T cell receptors (TCRs), and simultaneously express or secrete bispecific antibodies, cytokines, or other gene products in order to enhance survival, direct cytotoxicity, activation and/or antibody dependent cellular cytotoxicity (ADCC).
The company's state-of-the-art clinical cell manufacturing facility in Toa Baja, Puerto Rico, is custom designed to support the development and commercialization of cutting-edge T cell and NK cell therapies. By leveraging proprietary and robust T cell and NK cell expansion and engineering technologies, CytoImmune aims to deliver high-quality cell therapy solutions to its partners and nurture collaborations that propel the future of cell therapy, ultimately improving cancer patients’ lives.
"I am honored to take on this leadership role and am eager to continue working with the talented team at CytoImmune," said Dr. Vidal. "We are committed to developing innovative cell therapies that hold transformative potential for cancer patients. I look forward to leading the company as we advance our own pipeline and assist other biotechnology companies in developing innovative cellular therapies through our development and manufacturing services, thereby expanding our reach to more patients in need."
About CytoImmune Therapeutics:
As a leading biopharmaceutical company, CytoImmune Therapeutics is at the forefront of a novel natural killer cell therapy for lung cancer, currently in phase 1 clinical trials. In addition, we are now offering cell therapy development and clinical manufacturing services to both biotechnology companies and academia. Our state-of-the-art clinical cell manufacturing facility in Toa Baja, Puerto Rico, is custom built to support the development and commercialization of cutting-edge T cell or NK cell therapies. At CytoImmune, we are dedicated to fostering collaborations that drive the future of cell therapy and improve the lives of cancer patients. Discover how our expertise in cell therapy development and clinical manufacturing can accelerate your path to success. For additional information, please visit: Cytoimmune.com
Media Contact:
Albert Stichka
[email protected]
Albert Stichka, Elkordy Global Strategies, 1 6192544768, [email protected]
Share this article